Protagonist Therapeutics
PTGX
343 hedge funds and large institutions have $9.29B invested in Protagonist Therapeutics in 2026 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 140 increasing their positions, 88 reducing their positions, and 36 closing their positions.
75% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 36
74% more call options, than puts
Call options by funds: $51M | Put options by funds: $29.4M
59% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 88
12% more capital invested
Capital invested by funds: $8.3B → $9.29B (+$992M)
7% more funds holding
Funds holding: 320 → 343 (+23)
5.58% less ownership
Funds ownership: 123.43% → 117.85% (-5.6%)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$55.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$50.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$39.9M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$30.9M |
| 5 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$29.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$186M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$162M |
| 3 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
-$60.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$54.2M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$45.1M |
PTGX Hedge Fund Activity: Q2 2026 in Review
343 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2026, worth a combined $9.29B — up 12% from $8.3B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new PTGX positions and 36 closed out — a net gain of 27 holders — while 140 added to existing stakes and 88 trimmed.
The largest buyer was BlackRock, adding an estimated $55.2M. The largest seller was UBS Group, cutting an estimated $186M.
- 343 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2026, up from 320 in Q1 2026.
- Funds reported $9.29B of Protagonist Therapeutics stock for Q2 2026, up 12% quarter-over-quarter.
- 63 funds opened new Protagonist Therapeutics positions in Q2 2026 and 36 closed out, a net change of +27 holders.
- The largest Protagonist Therapeutics buyer in Q2 2026 was BlackRock, an estimated $55.2M added.
- The largest Protagonist Therapeutics seller in Q2 2026 was UBS Group, an estimated $186M sold.
Based on aggregated 13F filings for Q2 2026.